[Evaluation of the efficacy of xavin treatment of ischemic heart disease].
The results of ksavin treatment of 90 patients suffering from ischemic heart disease are discussed. Ksavin was given in a daily dose of 450-1,200 mg for 3 weeks. The clinical efficacy of the treatment was correlated with the risk factors and the indices of the ECG, centra hemodynamics and spiroergometry. The effect was good in 55% of the patients and satisfactory in 30%. No effect was produced in 15% of the patients. The best results were observed in younger patients with disease of short duration and no concomitant arterial hypertension. A favourable effect of ksavin on lipid metabolism and blood coagulation was noted. The study showed ksavin to be an effective measure in the treatment of ischemic heart disease.